Industry Overview - The U.S. cannabis industry is evolving as it approaches 2026, with growth being uneven but still presenting opportunities [1] - Operators are focusing on efficiency and profitability, while investors are monitoring federal reform progress [1][2] - Rescheduling discussions have improved overall sentiment, but capital access remains limited for many companies [1] Market Dynamics - Leading multi-state operators are building scale, with strong retail footprints providing steady revenue streams [2] - Brand development is crucial for defending margins as competition tightens, making operational discipline critical [2] - Stability is a priority for investors, with balance sheet strength and positive adjusted EBITDA trends being more important than rapid expansion [3] Key Markets - Florida, Illinois, Pennsylvania, and Ohio are identified as key battleground states with strong consumer demand [3] - Pricing pressure continues in mature regions, making scale and branding competitive advantages [3] Notable Companies - Ascend Wellness Holdings is refining operations and focusing on efficiency, with annual revenue in the half-billion-dollar range and positive adjusted EBITDA trends [4][9][10] - Cansortium, operating under the FLUENT brand, is focused on Florida and maintains a vertically integrated structure, with recent strategic moves improving its balance sheet [11][14][15] - Cresco Labs is one of the largest U.S. multi-state operators, with a broad footprint and strong brand presence, generating annual revenue exceeding several hundred million dollars [16][18][20] Financial Performance - Ascend has reported fluctuating quarterly revenue due to pricing pressure but has shown improvement in adjusted EBITDA margins [9] - Cansortium's revenue reflects industry volatility, but cost reductions have supported adjusted EBITDA stability [14] - Cresco has consistently maintained positive adjusted EBITDA, with liquidity improving following balance sheet adjustments [19]

Behind every puff of a vape, there's a battery. >> Oh, look at that disposable vape. And this might be the guy that knows that better than anyone out there.>> There is a lithium ion cell that is actually completely fully rechargeable. This ebike battery. >> When we first met Chris Dole, he was using the batteries from disposable vapes to power an ebike.Now he's taken the experiment to a whole new level. Chris collected 500 vapes that local shops were trying to get rid of and wired them up to power everythin ...

Core Viewpoint - MediPharm Labs Corp. is preparing for its Annual and Special Meeting of Shareholders on June 16, 2025, emphasizing the importance of shareholder support for its Board of Directors and strategic direction amidst a challenge from a dissident shareholder [1][2][6]. Financial Performance - In 2024, MediPharm reported a 27% year-over-year increase in net revenue and improved gross profit margin from 18% in 2023 to 31% [5]. - The company's Adjusted EBITDA loss narrowed by $8.3 million to $1.9 million in 2024 compared to the previous year, with expectations of reaching positive Adjusted EBITDA soon [5]. Strategic Developments - MediPharm has undergone a strategic revitalization, including the acquisition of VIVO Cannabis in March 2023, which has opened new international markets and contributed approximately $10 million in annual revenue from its Beacon brand in Australia [12][13]. - The company has streamlined operations, focusing on strategic business lines and reducing operating expenses by half through synergies from the VIVO acquisition [11][13]. Governance and Shareholder Engagement - The Board of Directors recommends shareholders vote using the GREEN proxy to support its nominees, highlighting concerns about the qualifications of dissident nominees from Apollo Technology Capital Corp. [2][6][16]. - MediPharm emphasizes its commitment to good governance practices, including an independent Chair and key committees, to enhance shareholder value [20][21]. Market Position and Future Outlook - MediPharm's product mix includes various cannabis products, with international sales exceeding 50% of revenues in recent quarters, positioning the company for growth in the medical cannabis sector [15]. - The company believes it has established a solid foundation for future growth and is committed to ongoing enhancements in governance and operational strategies [28][27].

Core Insights - Philip Morris is targeting a 13% to 15% growth in EPS for the year, reaffirming its guidance in a recent press release [2] - The company has been undergoing a smoke-free transformation for over 10 years, achieving its strongest growth since 2011, excluding the post-pandemic recovery [2] - Despite focusing on smoke-free products, the company is still seeing positive volume growth across its total business [3] Company Strategy - The emphasis is on transitioning from combustible products to smoke-free alternatives, including heat-not-burn and vaping products [3] - The company is committed to maintaining pressure on its combustible business while promoting smoke-free innovations [3]